2361 Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancer

Authors :: Kyu-Taek Lee
Joung-Soon Jang
Dae-Keun Lim
Nyun Jong Lee
In-Tae Hwang
Ju-Won Kang
Jun-Seong Yoon
Eun Mi Nam
Won Jongwoo
Suyeon Lee
Sung-Hwa Oh
Deukjo Hong
Sujin Bae
Seo-Young Song
Hyung-Jin Lee
Sue-Young Lee
Hyun-Gyu Lee
Kyusoon Kim
Hyun Jung Kim
Han Jo Kim
Source :: European Journal of Cancer. 51:S456
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
FOLFIRINOX
business.industry
medicine.disease
Second line chemotherapy
Gemcitabine
Oxaliplatin
Irinotecan
Refractory
Internal medicine
Pancreatic cancer
medicine
business
medicine.drug

Full Text Access

Tools